Two points:
First, to anyone who tries the “FDA won’t like it argument”, show them the paper I posted above. In the paper, FDA statisticians considered 5 ways to handle baseline data - they recommeneded 2 of them, neither of which corresponds to the naive “change from baseline” analysis. While this does not decisively refute the “FDA won’t like it” argument, it shows that they may be more open minded and thoughtful than we presume.
Second, I do not think technical statistical arguments should always rule the day. The clinical, regulatory, and business context do matter and must be considered. In some cases technical arguments should prevail and should be pushed vey hard; however in other cases, doing so is simply reckless. Statisticians should seek to avoid one-size-fits-all, context-free thinking. We should certainly be familiar with the technical drawbacks of “change from baseline”, but also understand the context of a specific study and exercise judgment on a case by case basis.